HECTD2

A roundup of this week's most newsworthy healthcare press releases from PR Newswire, including the 2025 Main Residency Match® results and a new "hands on" app for healthcare hand specialists. NEW YORK, March 28, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, March 24-28, 2025. Diabetes Alert Day: Know Your Risk "Nearly 1 in 2 Americans has diabetes or prediabetes. It's likely someone you know or love is impacted. We encourage everyone to heed this alert—learn your risk, be aware of the symptoms of diabetes, and don't wait to reach out to your doctor if you have any concerns," said Charles Henderson, the ADA's chief executive officer. National Resident Matching Program® Releases the 2025 Main Residency Match® Results, Celebrates the Next Generation of Physicians A total of 52,498 applicants registered for the Match (4.1% increase from 2024) to learn where they will begin their medical training. Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer The Wegovy® savings offer gives cash-paying patients or those with commercial insurance that does not cover obesity medicines access to a 28-day supply (one box) of Wegovy® for $499. Endo Launches Spatial Computing Simulator to Create a Fully Immersive Learning Environment for Hand Specialists The Spatial Computing Injection Simulator allows hand specialists to interact simultaneously with both physical and digital objects—blending a physical hand model and digital content via an Apple Vision Pro app—to help refine their injection technique. America's Silent Epidemic Worsens: Adverse Drug Events Now the Third Leading Cause of Death Research indicates that more than 94% of Adverse Drug Reactions (ADRs) are not reported by healthcare professionals, delaying the detection of safety signals and hindering accurate assessment of medication risks. Deloitte's 15th Annual Pharmaceutical Innovation Report: Pharma R&D Returns Continue Upward for Second Consecutive Year One key takeaway of the report is that GLP-1 therapies have played a significant role in driving this year's increase in returns, highlighting the return on investment (ROI) of addressing large, unmet medical needs. Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages. Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants Using custom-developed immunoassays, the combination of a primary adenovirus vaccine (COVID-19 Vaccine AstraZeneca) coupled with a CiVax™ booster was shown to induce broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series (such as the Moderna vaccine Spikefax® or the Pfizer vaccine Cominarty®) in humans. Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders Ricardo Dolmetsch, Ph.D., President and Chief Scientific Officer of Tempero Bio, said, "TMP-301 is a novel therapy that helps prevent relapse by targeting the underlying biology of addiction. This financing will allow us to advance TMP-301 through key proof of concept phase 2 studies in humans." NINJA Joins La Roche-Posay as New Partner in Cause for Skin Cancer Detection and Prevention "By sharing my personal experience far beyond my community, through the campaign with La Roche-Posay, I want to deliver a crucial message about skin cancer prevention: don't play games with detection," said Tyler "NINJA" Blevins, pro-gamer and melanoma survivor. MADD Sports and NDUR Join Forces to Tackle Mental Health and Impaired Driving on College and High School Campuses Nationwide The collaboration aims to redefine mental health support and empower young athletes to make safer, healthier decisions—on and off the field. At the heart of this powerful collaboration is NDUR's innovative mobile-first platform, which connects athletes directly to on-campus services, teletherapy, crisis intervention tools, and peer-to-peer support—anytime, anywhere. EnrollHere Acquires MyMedicareBot, Creating the Industry's First End-to-End Medicare Enrollment Ecosystem This strategic acquisition cements EnrollHere's position as the industry's first fully integrated Medicare ecosystem, enabling agencies and call centers to manage the entire sales process—from lead flow to policy issuance—on a single, seamless platform. Rare loss-of-function variants in HECTD2 and AKAP11 confer a risk of bipolar disorder Scientists at deCODE genetics, a subsidiary of Amgen, revealed associations between rare loss-of-function variants in two genes and bipolar disorder. International Institute for Brain Enhancement Partners with NeuralCure AI to Revolutionize PTSD Treatment for Veterans "With AI and neuroscience, we can map PTSD's impact on the brain and actively reverse it. This partnership allows us to apply these breakthroughs at scale, giving veterans a real chance at healing," said Dr. Philip DeFina, Chief Science Officer. Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations The partnership aims to integrate innovative new material science and disruptive technology like chairside 3D printing to optimize workflows, enhance procedural efficiency and benefit both patients and practitioners. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Scientists at deCODE genetics, a subsidiary of Amgen, reveal today in Nature Genetics associations between rare loss-of-function variants in two genes and bipolar disorder. REYKJAVIK, Iceland, March 25, 2025 /PRNewswire/ -- Bipolar disorder is characterized by extreme mood swings, bouts of mania or hypomania, and episodes of depression. It is a highly heritable and serious condition, that when untreated comes with a high suicide rate. While there are several mood-stabilizing drugs available to treat the disorder, pharmaceutical treatment of bipolar disorder can have difficult side-effects and better treatments are urgently needed. Continue Reading Rare loss-of-function variants in HECTD2 and AKAP11 confer risk of bipolar disorder Kari Stefansson CEO of decode genetics with Thorgeir Thorgeirsson and Vinicius Tragante, authors on the paper. (PRNewsfoto/deCODE genetics) Significant progress has occurred over the last 15 years through genome-wide association studies leading to the identification of hundreds of biomarkers, i.e. DNA sequence variants, associated with the risk of psychiatric disease, including bipolar disorder. These biomarkers represent common variations each carrying a small risk, but in confluence, they are beginning to account for a considerable part of the variance in psychiatric traits and disorders. Variants predicted to cause loss of function of genes tend to be rare but hold great promise for informing on the underlying biology. To harness the information contained in rare loss-of-function (LOF) variants, the scientists performed a variant burden analysis for bipolar disorder using gene-based aggregation of LOF variants in whole genome sequencing data from Iceland and the UK Biobank and using data from the Bipolar Exomes study (BipEx, ) for replication and further meta-analysis efforts. The study revealed the association of LOF variants in two genes (HECTD2 and AKAP11) with bipolar disorder. Both associations with bipolar disorder are novel, but AKAP11 has previously been associated with psychosis and schizophrenia. AKAP11 encodes an anchoring protein, that regulatory subunits of protein kinase A (PKA) bind to, leading to confinement of PKA to specific cellular locations. HECTD2 encodes an E3 ubiquitin ligase, that adds multiple ubiquitin groups to proteins, thereby labeling them for destruction by the proteasome. The products of both AKAP11 and HECTD2 interact with GSK3β, a protein inhibited by lithium, the most effective mood stabilizer available to treat bipolar disorder. These findings point to the dysfunction of specific cellular pathways in bipolar disorder and cast the gene products of AKAP11 and HECTD2 along with GSK3β as promising targets in the search for new treatments for bipolar disorder. Based in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. deCODE genetics is a wholly-owned subsidiary of Amgen. Video - Photo - Logo - SOURCE deCODE genetics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED